The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The Clinical Approach Towards Chondrosarcoma
Abstract
Learning Objectives: After completing this course, the reader will be able to: Classify the chondrosarcoma subtypes.Engage in the diagnostic process of chondrosarcoma.Evaluate the treatment options for chondrosarcoma. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com This review provides an overview of the histopathology, classification, diagnostic procedures, and therapy of skeletal chondrosarcoma. Chondrosarcomas that arise de novo are primary chondrosarcomas, whereas chondrosarcomas developing superimposed on pre-existing benign cartilage neoplasms such as enchondromas or osteochondromas are referred to as secondary chondrosarcomas. Conventional chondrosarcomas can be categorized according to their location in bone into central, peripheral, and juxtacortical chondrosarcomas. Histological grading is related to prognosis; however, it is also subject to interobserver variability. Rare subtypes of chondrosarcoma, including dedifferentiated, mesenchymal, and clear cell chondrosarcoma, are discussed as well. Magnetic resonance imaging is necessary to delineate the extent of the intraosseous and soft tissue involvement preoperatively. Computed tomography is especially recommended in the pelvis and other flat bones where it may be difficult to discern the pattern of bone destruction and the presence of matrix mineralization. Wide, en-bloc excision is the preferred surgical treatment in intermediate- and high-grade chondrosarcoma. In low-grade chondrosarcoma confined to the bone, extensive intralesional curettage followed by local adjuvant treatment and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control. Chondrosarcomas are relatively radiotherapy resistant; therefore, doses >60 Gy are needed in attempts to achieve local control after incomplete resection. Irradiation with protons or other charged particles seems beneficial in this curative situation. Chemotherapy is only possibly effective in mesenchymal chondrosarcoma, and is of uncertain value in dedifferentiated chondrosarcoma. Potential new systemic treatment targets are being discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K., & Mertens, F. (2002) · Lund University Publications (Lund University) · Cited by 4,467
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K. K., & Mertens, F. (2002) · Medical Entomology and Zoology · Cited by 2,073
Eble, J. N. (2004) · Medical Entomology and Zoology · Cited by 1,152
Evans, H. L., Ayala, A. G., & Romsdahl, M. M. (1977) · Cancer · doi:10.1002/1097-0142(197708)40:2<818::aid-cncr2820400234>3.0.co;2-b · Cited by 987
Proton radiation therapy for chordomas and chondrosarcomas of the skull base
Hug, E. B., Loredo, L. N., Slater, J. D., Devries, A., Grove, R. I., Schaefer, R. A., Rosenberg, A. E., & Slater, J. M. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.91.3.0432 · Cited by 510
Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1)
Ahn, J., Lüdecke, H.-J., Lindow, S., Horton, W. A., Lee, B., Wagner, M. J., Horsthemke, B., & Wells, D. E. (1995) · Nature Genetics · doi:10.1038/ng1095-137 · Cited by 432
The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate
McCormick, C., Leduc, Y., Martindale, D., Mattison, K., Esford, L., Dyer, A., & Tufaro, F. (1998) · Nature Genetics · doi:10.1038/514 · Cited by 384
Risk factors for survival and local control in chondrosarcoma of bone
Fiorenza, F., Abudu, A., Grimer, R. J., Carter, S. R., Tillman, R. M., Ayoub, K., Mangham, D. C., & Davies, A. M. (2002) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.84b1.0840093 · Cited by 360
The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes
Stickens, D., Clines, G., Burbee, D., Ramos, P., Thomas, S., Hogue, D., Hecht, J. T., Lovett, M., & Evans, G. A. (1996) · Nature Genetics · doi:10.1038/ng0996-25 · Cited by 338
Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group
Grimer, R. J., Gosheger, G., Taminiau, A., Biau, D., Matejovsky, Z., Kollender, Y., San-Julian, M., Gherlinzoni, F., & Ferrari, C. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.016 · Cited by 235
Self-citationCartilaginous Tumors: Fast Contrast-enhanced MR Imaging
Geirnaerdt, M. J. A., Hogendoorn, P. C. W., Bloem, J. L., Taminiau, A. H. M., & van der Woude, H.-J. (2000) · Radiology · doi:10.1148/radiology.214.2.r00fe12539 · Cited by 230
Self-citationUpdates on the cytogenetics and molecular genetics of bone and soft tissue tumors
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00002-5 · Cited by 214
Bovée, J. V., Cleton-Jansen, A.-M., Taminiau, A. H., & Hogendoorn, P. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70282-5 · Cited by 211
Self-citationPositional cloning of a gene involved in hereditary multiple exostoses
Wuyts, W. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.10.1547 · Cited by 195
Dedifferentiated Chondrosarcoma: The Role of Chemotherapy with Updated Outcomes
Dickey, I. D., Rose, P. S., Fuchs, B., Wold, L. E., Okuno, S. H., Sim, F. H., & Scully, S. P. (2004) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200411000-00008 · Cited by 194
Bovée, J. V. M. G., Cleton-Jansen, A.-M., Wuyts, W., Caethoven, G., Taminiau, A. H. M., Bakker, E., Van Hul, W., Cornelisse, C. J., & Hogendoorn, P. C. W. (1999) · The American Journal of Human Genetics · doi:10.1086/302532 · Cited by 193
Self-citationHistological Typing of Bone Tumours
Schajowicz, F. (1993) · Springer eBooks · doi:10.1007/978-3-642-84902-2 · Cited by 181
Reliability of Histopathologic and Radiologic Grading of Cartilaginous Neoplasms in Long Bones
the Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group (2007) · The Journal of Bone & Joint Surgery · doi:10.2106/jbjs.f.01530 · Cited by 164
Mangham, D. C. (2004) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.86b3.0860466b · Cited by 146
Bovée, J. V. M. G., den Broek, L. J. C. M. V., Cleton-Jansen, A., & Hogendoorn, P. C. W. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780202 · Cited by 145
Self-citationReliability of Histopathologic and Radiologic Grading of Cartilaginous Neoplasms in Long Bones
Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group (2007) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200710000-00003 · Cited by 130
The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions
Hameetman, L., Szuhai, K., Yavas, A., Knijnenburg, J., van Duin, M., van Dekken, H., Taminiau, A. H. M., Cleton-Jansen, A. M., Bovée, J. V. M. G., & Hogendoorn, P. C. W. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk067 · Cited by 120
Self-citationBovée, J. V. M. G., Cleton-Jansen, A., Kuipers‐Dijkshoorn, N. J., den Broek, L. J. C. M. V., Taminiau, A. H. M., Cornelisse, C. J., & Hogendoorn, P. C. W. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199911)26:3<237::aid-gcc8>3.3.co;2-c · Cited by 106
Self-citationHerbst, R. S., Mendolson, D. S., Ebbinghaus, S., Gordon, M. S., O'Dwyer, P. J., Lieberman, G. S., Ing, J., Kurzrock, R., Novotny, W. F., & Eckhardt, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3013 · Cited by 103
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas
Rozeman, L. B., Hameetman, L., Cleton-Jansen, A., Taminiau, A. H. M., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2005) · The Journal of Pathology · doi:10.1002/path.1723 · Cited by 97
Self-citationvan Beerendonk, H. M., Rozeman, L. B., Taminiau, A. H. M., Sciot, R., Bovée, J. V. M. G., Cleton-Jansen, A., & Hogendoorn, P. C. W. (2004) · The Journal of Pathology · doi:10.1002/path.1517 · Cited by 92
Self-citationLarramendy, M. L., Tarkkanen, M., Valle, J., Kivioja, A., Ervasti, H., Karaharju, E., Salmivalli, T., Elomaa, I., & Knuutila, S. (1997) · Europe PMC (PubMed Central) · Cited by 82
p53 Expression and DNA ploidy of cartilage lesions
Coughlan, B., Feliz, A., Ishida, T., Czerniak, B. A., & Dorfman, H. D. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90166-3 · Cited by 71
Wyman, J. J., Hornstein, A. M., Meitner, P. A., Mak, S., Verdier, P., Block, J. A., Pan, J., & Terek, R. M. (1999) · Journal of Orthopaedic Research® · doi:10.1002/jor.1100170619 · Cited by 70
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo
Klenke, F. M., Abdollahi, A., Bertl, E., Gebhard, M. M., Ewerbeck, V., Huber, P. E., & Sckell, A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-49 · Cited by 67
Genetics of chondrosarcoma and related tumors
Sandberg, A. A. (2004) · Current Opinion in Oncology · doi:10.1097/01.cco.0000129678.72521.e5 · Cited by 67
Genetic and Epigenetic Alterations in Tumor Progression in a Dedifferentiated Chondrosarcoma
Röpke, M., Boltze, C., Neumann, H., Roessner, A., & Schneider‐Stock, R. (2003) · Pathology - Research and Practice · doi:10.1078/0344-0338-00443 · Cited by 65
Nooij, M. A., Whelan, J. S., Bramwell, V. H. C., Taminiau, A. T., Cannon, S. R., Hogendoorn, P. C. W., Pringle, J. A. S., Uscinska, B., Weeden, S., Kirkpatrick, A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.026 · Cited by 60
Self-citationCleton-Jansen, A., van Beerendonk, H. M., Baelde, H. J., Bovée, J. V. M. G., Karperien, M., & Hogendoorn, P. C. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1253 · Cited by 57
Self-citationClear cell chondrosarcoma: a pathological and immunohistochemical study
Masui, Ushigome, & Fujii (1999) · Histopathology · doi:10.1046/j.1365-2559.1999.00656.x · Cited by 33
Cited by
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Self-citationCasali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationKrishnan, Y., & Grodzinsky, A. J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.005 · Cited by 443
Doyle, L. A. (2014) · Cancer · doi:10.1002/cncr.28657 · Cited by 424
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets
Bovée, J. V. M. G., Hogendoorn, P. C. W., Wunder, J. S., & Alman, B. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2869 · Cited by 283
Self-citation
Metadata
- Authors
- Gelderblom, H., Hogendoorn, P. C. W., Dijkstra, S. D., van Rijswijk, C. S., Krol, A. D., Taminiau, A. H. M., & Bovée, J. V. M. G.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-01
- Volume
- 13
- Issue
- 3
- Pages
- 320-329
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2150312029
- Cited by
- 756
- References
- 36
- FWCI
- 17.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.